588676-02-2

Basic information

• Product Name: 4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE
• Synonyms: CHEMBRDG-BB 3014213;ART-CHEM-BB B014213;AKOS B014213;4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE;4-[(3-bromobenzyl)oxy]benzaldehyde(SALTDATA: FREE);IVK/1265305;ZINC02558331
• CAS NO: 588676-02-2
• Molecular Formula: C₁₄H₁₁BrO₂
• Molecular Weight: 291.14
• Mol File: 588676-02-2.mol

Chemical Properties

• Melting Point: 65-69 °C(Solv: isopropyl acetate (108-21-4); heptane (142-82-5))
• Boiling Point: 419.3°C at 760 mmHg
• Flash Point: 207.4°C
• Appearance: /
• Density: 1.441g/cm³
• Vapor Pressure: 3.07E-07mmHg at 25°C
• Refractive Index: 1.629
• CAS DataBase Reference: 4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE(588676-02-2)
• EPA Substance Registry System: 4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE(588676-02-2)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 588676-02-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to serve as a versatile building block in organic chemistry. Its functional groups contribute to the development of a range of medicinal compounds.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE is utilized as a key intermediate due to its capacity to undergo further chemical reactions, making it instrumental in creating a variety of organic compounds.
Used in Dye Production:
4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE is employed in the production of dyes, capitalizing on its chemical structure to contribute to the color properties of the dyes.
Used in Perfumery:
The aromatic fragrance characteristic of 4-(3-BROMO-BENZYLOXY)-BENZALDEHYDE makes it a component in the creation of perfumes, where its scent is used to enhance the olfactory profiles of fragrances.

InChI:InChI=1/C14H11BrO2/c15-13-3-1-2-12(8-13)10-17-14-6-4-11(9-16)5-7-14/h1-9H,10H2

Upstream product

• 15852-73-0 (3-Bromophenyl)methanol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 932-77-4 3-bromobenzyl chloride 
• 823-78-9 meta-bromobenzyl bromide 

Downstream Products

• 1204473-96-0 5-(4-(3-bromobenzyloxy)benzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 865231-46-5 (-)-AMG 837 
• 1372195-41-9 4-((2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde 
• 691904-24-2 5-(4-([1,1'-biphenyl]-3-ylmethoxy)benzyl)thiazolidine-2,4-dione 
• 929713-64-4 4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde 
• 1414806-67-9 (S,E)-2-(5-(4-(3-bromobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 
• 1237025-10-3 (2R,3S,Z)-6-(4-(3-bromobenzyloxy)benzylidene)-3,4-dimethyl-2-phenyl-1,4-oxazepane-5,7-dione 

Relevant articles and documents

Nickel-catalyzed olefin asymmetric hydrogen alkynylation method and application of nickel-catalyzed olefin asymmetric hydrogen alkynylation method in preparation of AMG837

The invention discloses a nickel-catalyzed olefin asymmetric hydroalkynylation method and an application of nickel-catalyzed olefin asymmetric hydroalkynylation in preparation of AMG837, and belongs to the field of organic chemistry and medicinal chemistry. According to the invention, under the action of metal nickel salt, chiral ligand, alkali, hydrogen source, additive and the like, olefin and alkynyl bromide are reacted in an organic solvent, so the benzyl alkynyl substituted compound is obtained with excellent regioselectivity and enantioselectivity. According to the method, cheap transition metal nickel is used as a catalyst, commercially available olefin and alkynyl bromide are used as raw materials, conditions are mild, functional group compatibility is good, and operation is easy and convenient.

Morpholine amide derivative and application thereof

The invention discloses a morpholine amide derivative and application thereof, and particularly relates to a novel morpholine amide derivative and a pharmaceutical composition containing the compound.The invention also relates to a method for preparing th

PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF

Provided a pyrrolidineamide compound and a pharmaceutical composition containing this compound which can be used as a MAO-B inhibitor. Also provided methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a m

Nitrogen-containing heterocyclic amide derivative and use thereof

The present invention discloses a nitrogen-containing heterocyclic amide derivative and use thereof, and in particular, the present invention relates to a novel class of nitrogen-containing heterocyclic amide derivatives and pharmaceutical compositions co

Guanylthiourea derivatives as potential antimalarial agents: Synthesis, in?vivo and molecular modelling studies

Guanylthiourea (GTU) derivatives were identified as possible anti-malarial agents, recently, using in?vitro studies on Plasmodium falciparum. This article gives an account of the in?vivo anti-malarial activity of GTU derivatives against experimental rodent malaria. A total of 20 synthesized GTU derivatives were evaluated for in?vivo antimalarial activity, out of which six showed encouraging results; one compound appeared to have curative potential. Molecular docking and molecular dynamics analysis were carried out to understand the molecular level interactions.

Design, synthesis, and biological evaluation of novel thiazolidinediones as PPAR3/FFAR1 dual agonists

Diabetes mellitus is a chronic metabolic disorder that affects more than 180 million people worldwide. Peroxisome proliferator activated receptors (PPARs) are a group of nuclear receptors that have been targeted by the thiazolidinedione (TZD) class of compounds for the management of type II diabetes. PPAR3 is known to regulate adipogenesis and glucose metabolism. Another emerging target for the design of antidiabetic agents is the free fatty acid receptor 1 (FFAR1), previously known as GPR40. Agonists of this receptor were found to enhance insulin secretion in diabetic patients. It has been reported that some thiazolidinediones (TZDs) activate FFAR1 with micromolar potency. In this study, based on docking studies into the crystal structure of PPAR3 and a homology model of FFAR1, nineteen compounds were designed, synthesized, and biologically tested for agonistic activity on both receptors. Nine compounds showed promising dual activity, with two compounds, 11a and 5b, having affinities in the low micromolar range on both targets. These molecules represent the first antidiabetic agents that could act as insulin sensitizers as well as insulin secretagogues.

Synthesis and antimicrobial evaluation of L-phenylalanine-derived C5-substituted rhodanine and chalcone derivatives containing thiobarbituric acid or 2-thioxo-4-thiazolidinone

Four novel series of compounds, including the l-phenylalanine-derived C5-substituted rhodanine (6a-q, 7a-j) and chalcone derivatives containing thiobarbituric acid or 2-thioxo-4-thiazolidinone (9a-e, 11a-e) have been designed, synthesized, characterized, and evaluated for their antibacterial activity. Some of these compounds showed significant antibacterial activity against Gram-positive bacterias, especially against the strains of multidrug-resistant clinical isolates, among which compounds 6c-e, 6g, 6i, 6j and 6q exhibiting high levels of antimicrobial activity against Staphylococcus aureus RN4220 with minimum inhibitory concentration (MIC) values of 2 μg/mL. Compound 6q showed the most potent activity of all of the compounds against all of the test multidrug-resistant clinical isolates tested. Unfortunately, however, none of the compounds were active against Gram-negative bacteria at 64 μg/mL.

Asymmetric syntheses of a GPR40 receptor agonist via diastereoselective and enantioselective conjugate alkynylation

Two asymmetric methods to synthesize a potent GPR40 receptor agonist are reported. Both synthetic routes utilize readily available, inexpensive starting materials and reagents. The first route relies on a highly diastereoselective conjugate alkynylation of an ephedrine-derived oxazepanedione acceptor. The second route features the enantioselective alkynylation of a Meldrum's acid-derived acceptor mediated by a chiral zinc cinchonidine reagent.

Practical asymmetric conjugate alkynylation of meldrum's acid-derived acceptors: Access to chiral β-alkynyl acids

(Chemical Equation Presented) The enantioselective conjugate addition of alkynyl nucleophiles has been a long-standing challenge in synthetic chemistry. This paper describes a highly practical asymmetric conjugate alkynylation of Meldrum's acid-derived acceptors using cinchonidine ($100/kg) as the chiral mediator. The process provides practical access to chiral β-alkynyl acids. Noteworthy attributes of the method are its broad scope, high functional-group compatibility, and ease of scalability. Copyright

OXADIAZOLIDINEDIONE COMPOUND

[Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.